Table 1: Definitions Used in the AJCC Lung Cancer Staging System
Table 2: AJCC Staging of NSCLC
Table 3: Symptoms of NSCLC
Table 4: Prognostic Factors for NSCLC
Table 5: Prognosis for NSCLC Based on Initial Staging
Table 6: Risk Factors and Comorbidities for Lung Cancer
Table 7: Histological Subtype Distribution Among NSCLC
Table 8: 8MM, Relative Survival
Table 9: 8MM, Sources Used for Diagnosed Incidence of NSCLC
Table 10: 8MM, Sources Used for Cancer Stage at Diagnosis
Table 11: 8MM, Sources Used for NSCLC by Histological Subtypes
Table 12: US, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 13: 5EU, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 14: Japan, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 15: China (Urban), Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 16: 8MM, Sources Used for Relative Survival of NSCLC
Table 17: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, Select Years 2015–2025
Table 18: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N (Row %), 2015
Table 19: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages ≥18 Years, N (Row %), 2015
Table 20: 8MM, Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis, Ages ≥18 Years, N, 2015
Table 21: 8MM, Diagnosed Incident Cases of NSCLC by Histological Subtypes, Ages ≥18 Years, N, 2015
Table 22: 8MM, Mutations Among Diagnosed Incident Cases of ADC, Both Sexes, Ages ≥18 Years, N, 2015
Table 23: 8MM, Mutations Among Diagnosed Incident Cases of SCC, Both Sexes, Ages ≥18 Years, N, 2015
Table 24: 8MM, Mutations Among Diagnosed Incident Cases of NSCLC, Both Sexes, N, Ages ≥18 Years, 2015
Table 25: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, Select Years 2015–2025
Table 26: 8MM, Alternate Forecast, Diagnosed Incident Cases of NSCLC by Histology Subtypes, Ages ≥18 Years, N, 2015 and 2025
Table 27: 8MM, Alternate Forecast, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, Select Years 2015–2025
Table 28: Prevalence of Brain and Bone Metastases in NSCLC
Table 29: Biomarker Testing Rates in Nonsquamous NSCLC
Table 30: Biomarker Testing Rates in Squamous NSCLC
Table 31: Treatment Guidelines for NSCLC
Table 32: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015–2025
Table 33: Country Profile – US
Table 34: Country Profile – France
Table 35: Country Profile – Germany
Table 36: Country Profile – Italy
Table 37: Country Profile – Spain
Table 38: Country Profile – UK
Table 39: Country Profile – Japan
Table 40: Country Profile – China
Table 41: Leading Treatments for NSCLC, 2016
Table 42: Marketed EGFR TKIs in NSCLC
Table 43: Product Profile – Tarceva
Table 44: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC
Table 45: Efficacy of Tarceva in Maintenance Therapy in NSCLC
Table 46: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC
Table 47: Safety of Tarceva
Table 48: Tarceva SWOT Analysis, 2016
Table 49: Product Profile – Iressa
Table 50: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)
Table 51: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)
Table 52: Safety of Iressa
Table 53: Iressa SWOT Analysis, 2016
Table 54: Product Profile – Gilotrif
Table 55: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 56: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 57: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC
Table 58: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC
Table 59: Safety of Gilotrif
Table 60: Gilotrif SWOT Analysis, 2016
Table 61: Product Profile – Tagrisso
Table 62: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC
Table 63: Safety of Tagrisso
Table 64: Tagrisso SWOT Analysis, 2016
Table 65: Product Profile – Portrazza
Table 66: Efficacy of Portrazza in First-Line, Squamous NSCLC
Table 67: Safety of Portrazza
Table 68: Portrazza SWOT Analysis, 2016
Table 69: Efficacy of Conmana in 2L Advanced NSCLC
Table 70: Efficacy of Conmana in 1L EGFR-mutant NSCLC
Table 71: Safety of Conmana
Table 72: Conmana SWOT Analysis, 2016
Table 73: Marketed ALK TKIs in NSCLC
Table 74: Product Profile – Xalkori
Table 75: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC
Table 76: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC
Table 77: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC
Table 78: Safety of Xalkori in Previously Treated, Metastatic NSCLC
Table 79: Xalkori SWOT Analysis, 2016
Table 80: Product Profile – Zykadia
Table 81: Efficacy of Zykadia
Table 82: Safety of Zykadia
Table 83: Zykadia SWOT Analysis, 2016
Table 84: Product Profile – Alecensa
Table 85: Efficacy of Alecensa
Table 86: Efficacy of Alecensa in NSCLC patients with CNS lesions
Table 87: Safety of Alecensa
Table 88: Alecensa SWOT Analysis, 2016
Table 89: Marketed PD-1/PD-L1 ICIs in NSCLC
Table 90: Product Profile – Opdivo
Table 91: Efficacy of Opdivo in Metastatic Squamous NSCLC
Table 92: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC
Table 93: Safety of Opdivo
Table 94: Opdivo SWOT Analysis, 2016
Table 95: Product Profile – Keytruda
Table 96: Efficacy of Keytruda
Table 97: Safety of Keytruda
Table 98: Keytruda SWOT Analysis, 2016
Table 99: Product Profile – Tecentriq (atezolizumab)
Table 100: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)
Table 101: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 102: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)
Table 103: Patient Demographics in the Phase II FIR Trial (NCT01846416)
Table 104: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 105: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)
Table 106: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 107: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 108: Tecentriq SWOT Analysis, 2016
Table 109: Product Profile – Avastin
Table 110: Efficacy of Avastin in Nonsquamous NSCLC
Table 111: Safety of Avastin
Table 112: Avastin SWOT Analysis, 2016
Table 113: Product Profile – Cyramza
Table 114: Efficacy of Cyramza
Table 115: Safety of Cyramza
Table 116: Cyramza SWOT Analysis, 2016
Table 117: Product Profile – Vargatef
Table 118: Efficacy of Vargatef in ADC NSCLC
Table 119: Safety of Vargatef in ADC NSCLC
Table 120: Vargatef SWOT Analysis, 2016
Table 121: Summary of Chemotherapies, 2015
Table 122: Unmet Need and Opportunity in NSCLC
Table 123: Product Profile – Yervoy (ipilimumab)
Table 124: Demographics in the Phase II NCT00527735 Trial
Table 125: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 126: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)
Table 127: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 128: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 129: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 130: Yervoy SWOT Analysis, 2016
Table 131: Product Profile – Avelumab (MSB-0010718C)
Table 132: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 133: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 134: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC
Table 135: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)
Table 136: Efficacy of Avelumab in Treatment-Naïve NSCLC
Table 137: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC
Table 138: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 139: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)
Table 140: Avelumab SWOT Analysis, 2016
Table 141: Product Profile – Durvalumab (MEDI4736)
Table 142: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial
Table 143: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial
Table 144: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II
Table 145: Efficacy of Durvalumab in Treatment-Naïve NSCLC
Table 146: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial
Table 147: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 148: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)
Table 149: Safety of Durvalumab in Treatment-Naïve NSCLC
Table 150: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 151: Durvalumab SWOT Analysis, 2016
Table 152: Product Profile – Naquotinib Mesylate (ASP8273)
Table 153: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials
Table 154: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 155: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 156: Naquotinib SWOT Analysis, 2016
Table 157: Product Profile – Olmutinib (BI 1482694; HM61713)
Table 158: Demographics in the Phase I/II NCT01588145 Trial
Table 159: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 160: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 161: Olmutinib SWOT Analysis, 2016
Table 162: Product Profile – Dacomitinib
Table 163: Demographics in the Phase II NCT00818441 Trial
Table 164: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial
Table 165: Safety of Dacomitinib in Phase II NCT00818441 Trial
Table 166: Dacomitinib SWOT Analysis, 2016
Table 167: Product Profile – Ensartinib
Table 168: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)
Table 169: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 170: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial
Table 171: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)
Table 172: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 173: Ensartinib SWOT Analysis, 2016
Table 174: Product Profile – Brigatinib
Table 175: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)
Table 176: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 177: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases
Table 178: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 179: Brigatinib SWOT Analysis, 2016
Table 180: Product Profile – CimaVax-EGF
Table 181: Demographics in the Phase III trial of the CimaVax-EGF in Cuba
Table 182: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba
Table 183: Safety of the CimaVax-EGF in the Phase III Trial in Cuba
Table 184: CimaVax-EGF SWOT Analysis, 2016
Table 185: Product Profile – Tedopi
Table 186: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC
Table 187: Efficacy of Tedopi in Advanced NSCLC
Table 188: Tedopi SWOT Analysis, 2016
Table 189: Product Profile – Anlotinib
Table 190: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial
Table 191: Anlotinib SWOT Analysis, 2016
Table 192: Product Profile – Aitan
Table 193: Efficacy of Aitan in Pretreated Nonsquamous NSCLC
Table 194: Aitan SWOT Analysis, 2016
Table 195: Product Profile – Fruquintinib
Table 196: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib
Table 197: Efficacy of Fruquintinib in Advanced Solid Tumors
Table 198: Safety of Fruquintinib in Advanced Solid Tumors
Table 199: Fruquintinib SWOT Analysis, 2016
Table 200: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)
Table 201: Product Profile – Abemaciclib
Table 202: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)
Table 203: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)
Table 204: Safety of Abemaciclib in Combination with Multiple Single Agents
Table 205: Abemaciclib SWOT Analysis, 2016
Table 206: Product Profile – Tafinlar + Mekinist
Table 207: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)
Table 208: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 209: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 210: Tafinlar + Mekinist SWOT Analysis, 2016
Table 211: Product Profile – Veliparib
Table 212: Demographics in the Phase II NCT01560104 Trial
Table 213: Efficacy of VCP in Advanced NSCLC (NCT01560104)
Table 214: Efficacy of VCP by Smoking Status (NCT01560104)
Table 215: Safety of VCP in Advanced NSCLC (NCT01560104)
Table 216: Veliparib SWOT Analysis, 2016
Table 217: Product Profile – Seribantumab (MM-121)
Table 218: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in
Table 219: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 220: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 221: MM-121 SWOT Analysis, 2016
Table 222: Product Profile – Sacituzumab govitecan (IMMU-132)
Table 223: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)
Table 224: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 225: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor
Table 226: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 227: IMMU-132 SWOT Analysis, 2016
Table 228: Product Profile – Plinabulin
Table 229: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 230: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 231: Plinabulin SWOT Analysis, 2016
Table 232: Early-Stage Clinical Development in NSCLC
Table 233: MET Status in the Phase II (NCT01610336) Trial
Table 234: Efficacy of Capmatinib + Iressa in MET+ NSCLC
Table 235: Demographics in the Phase II LURET Study
Table 236: Efficacy of Caprelsa in RET+ NSCLC
Table 237: Demographics in the Stage I of the Phase II NCT01639508 Trial
Table 238: Efficacy of Cometriq in RET+ NSCLC
Table 239: Key Companies in the NSCLC Market in the 8MM, 2015–2025
Table 240: Roche/Genentech’s NSCLC Portfolio Assessment, 2016
Table 241: Eli Lilly’s NSCLC Portfolio Assessment, 2016
Table 242: Pfizer’s NSCLC Portfolio Assessment, 2016
Table 243: AZ’s NSCLC Portfolio Assessment, 2016
Table 244: BMS’ NSCLC Portfolio Assessment, 2016
Table 245: Merck & Co.’s NSCLC Portfolio Assessment, 2016
Table 246: Novartis’ NSCLC Portfolio Assessment, 2016
Table 247: BI’s NSCLC Portfolio Assessment, 2016
Table 248: NSCLC – Global Drivers and Barriers, 2015‒2025
Table 249: Key Events Impacting Sales for NSCLC in the US, 2016
Table 250: NSCLC –Drivers and Barriers in the US, 2015‒2025
Table 251: Key Events Impacting Sales for NSCLC in the 5EU, 2016
Table 252: NSCLC –Drivers and Barriers in the 5EU, 2015‒2025
Table 253: Key Events Impacting Sales for NSCLC in Japan, 2016
Table 254: NSCLC –Drivers and Barriers in Japan, 2015‒2025
Table 255: Key Events Impacting Sales for NSCLC in China, 2016
Table 256: NSCLC –Drivers and Barriers in urban China, 2015-2025
Table 257: Key Launch Dates – Part I
Table 258: Key Launch Dates – Part II
Table 259: Key Patent Expiries
Table 260 Average Body Weight and Surface Area Across the 8MM
Table 261: Average Cost of Therapy of Alimta in the 8MM
Table 262: Average Cost of Therapy of Alecensa in the 8MM
Table 263: Average Cost of Therapy of Avastin
Table 264: Average Cost of Therapy of Cyramza
Table 265: Average Cost of Therapy of Gilotrif
Table 266: Average Cost of Therapy of Iressa
Table 267: Average Cost of Therapy of Portrazza
Table 268: Average Cost of Therapy of Tagrisso
Table 269: Average Cost of Therapy of Tarceva
Table 270: Average Cost of Therapy of Vargatef
Table 271: Average Cost of Therapy of Xalkori
Table 272: Average Cost of Therapy of Zykadia
Table 273: Average Cost of Therapy of Keytruda
Table 274: Average Cost of Therapy of Opdivo
Table 275: Average Cost of Therapy of Tecentriq
Table 276: Average Cost of Therapy of Conmana
Table 277: High-Prescribing Physicians Surveyed by Country